Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study

INTRODUCTION: Febrile neutropenia (FN) is a serious and frequent complication of cytotoxic chemotherapy. Biosimilar filgrastim (Nivestim™, Hospira Inc, A Pfizer Company, Lake Forest, IL, USA) is a granulocyte-colony stimulating factor licensed for the treatment of neutropenia and FN induced by myelo...

Descripción completa

Detalles Bibliográficos
Autores principales: Fruehauf, Stefan, Otremba, Burkhard, Stötzer, Oliver, Rudolph, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083766/
https://www.ncbi.nlm.nih.gov/pubmed/27743353
http://dx.doi.org/10.1007/s12325-016-0419-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083766/
https://www.ncbi.nlm.nih.gov/pubmed/27743353
http://dx.doi.org/10.1007/s12325-016-0419-1

Ejemplares similares